CONMED Corp. 10-Q Summary: Quarter Ended September 30, 1997
Business Context and Reporting Period
CONMED Corporation, a developer, manufacturer, and marketer of disposable medical products and related devices, filed its Form 10-Q for the quarter and nine months ended September 30, 1997. The company is headquartered in Utica, New York. As of November 8, 1997, there were 15,003,203 shares of common stock outstanding.
Key Financial Metrics
| Metric | 3 Months Ended Sep 1997 | 9 Months Ended Sep 1997 |
|---|---|---|
| Net Sales | $38,581,000 | $100,760,000 |
| Net Income | $4,517,000 | $10,451,000 |
| Earnings Per Share (EPS) | $0.30 | $0.69 |
| Gross Margin | 44.0% | 46.1% |
| Operating Income | $6,924,000 | $15,567,000 |
| Cash and Equivalents (Sep 30, 1997) | $5,159,000 | |
| Net Cash from Operations (9 Months) | $16,215,000 | |
| Total Debt | $0 (No borrowings outstanding) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22.7% in the third quarter and 9.0% for the nine-month period compared to 1996. This growth was primarily driven by the July 1, 1997, acquisition of a product line from Davol Inc. (approx. $25 million annual sales) and the inclusion of the New Dimensions in Medicine (NDM) acquisition in the full 1996 comparison.
- Profitability: While net income increased in the quarter ($4.5M vs $4.0M), it decreased for the nine-month period ($10.5M vs $11.5M). This decline was due to a $2.328 million pre-tax facility consolidation charge in Q1 1997 and lower gross margins from the Davol acquisition and pricing pressures on ECG electrodes.
- Liquidity: Cash and cash equivalents decreased significantly from $20.17 million (Dec 1996) to $5.16 million (Sep 1997). This reduction was caused by the $24 million cash acquisition of the Davol product line and a $4 million purchase of a building in Utica, NY.
- Debt Status: The company repaid all indebtedness ($65 million) in March 1996 using proceeds from a stock offering. There were no borrowings outstanding under its $60 million credit facility during the nine months ended September 1997.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes the decline in gross margin percentage (44.0% in Q3 vs 47.6% in Q3 1996) to the Davol product line, which currently has a lower margin profile. Sales force realignment in early 1997 and the discontinuation of dealer incentives negatively impacted sales in the first half of 1997.
- Facility Consolidation: A $2.328 million charge was recorded in Q1 1997 for closing the Dayton, Ohio facility. Operations were successfully transferred to New York facilities in Q2 and Q3 1997.
- Stock Repurchase: The Board authorized a $30 million stock repurchase program in May 1997. The company repurchased 25,000 shares for approximately $419,000 in Q3 1997.
- Liquidity Outlook: Management believes cash from operations, current resources, and the $60 million credit facility are sufficient for working capital and capital expenditures.
- Risks: Forward-looking statements are subject to risks including market conditions, the success of the sales force realignment, and the integration of acquired product lines.
Investor Verification Checklist
- Verify the integration progress and margin improvement trajectory of the newly acquired Davol product line.
- Confirm the status of the $30 million stock repurchase program and future buyback activity.
- Monitor the impact of the sales force realignment on future revenue growth rates.
- Review the utilization of the $60 million credit facility given the significant drop in cash reserves.
- Assess the long-term cost savings realized from the Dayton facility closure against the initial $2.3 million charge.